EURAMY at conferences
Poster presentation by Dr. M. Dumoulin (WP1):
"Investigating the mechanism of amyloid fibril formation by human lysozyme using single-domain camelid antibody fragments."
P. Chan, E. Pardon, J. Christodoulou, J.R. Kumita, E. De Genst, S. Muyldermans, C. Redfield, C.V. Robinson, A. Matagne, L. Wyns, C.M. Dobson, and M. Dumoulin.
Poster presented at VII European Symposium of the Protein Society, May 12-16, 2007, Stockholm/Uppsala, Sweden and,
Joint meeting of the Belgian Biophysical Society and the Belgian Physical Society, May 30 2007, Antwerpen, Belgium.
Contributions by Prof. Dr. med. C. Röcken (WP2, 5 and 6):
Lecture at the 38. Annual meeting of the German Society of Nephrology in Munich, Germany
Special lecture at the 21st Congress of the European Society of Pathology in Istanbul, Turkey
Contributions by Dr. B. Hazenberg (WP6 and 7):
1. Dutch Internist Days, Maastricht, 25-27 April 2007.
A. Up-to-date general lecture Bouke P.C. Hazenberg: Diagnostic dilemmas and developments in Amyloidosis
B. Meet the experts lectures Pieter van Paassen and Bouke P.C. Hazenberg: Amyloidosis
2. National congress of Portuguese Nephrologists, Vilamoura, 24 May 2007.
General lecture Bouke P.C. Hazenberg: Now and beyond in the Treatment and Management of AA amyloidosis
3. EULAR, Barcelona, 13-16 June 2007.
Poster Bouke P.C. Hazenberg, et al: Serum amyloid P component (SAP) concentration as a tool for measuring the amount of amyloid in abdominal fat tissue
Poster Jiska Meijer, et al: Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?
Abstract Aldert J.C. Hazenberg, et al: Laryngeal presentation of systemic amyloidosis in patients with apolipoprotein A1 L174S and L178P
4. The 64th ERA-EDTA congress. Ortho Biotech/Janssen-Cilag mini symposium, Barcelona, 23 June 2007. General lecture Bouke P.C. Hazenberg: AA amyloidosis: the disease, its diagnosis, and treatment strategies.
5. Meeting of the Swiss Society of Nephrology, Lausanne, 6 December 2007
Oral presentation Bouke P.C. Hazenberg, on behalf of the EFAAT group: Continued effectiveness of eprodisate in the preservation of renal function in AA amyloidosis patients: 3-year follow-up results
6. Dutch Symposium on Systemic diseases, Groningen, 8 February 2008
Lecture Bouke P.C. Hazenberg: Therapeutic developments in Amyloidosis
7. International symposium and meeting on “Systemic amyloidosis and related issues”, Berlin, 15 and 16 February 2008
Oral presentation Bregje van Schijndel: Diagnostic performance of a qualitative immunochemical method for detecting ATTR amyloidosis in aspirated fat tissue
Poster Johan Bijzet et al: Immunochemical analysis of serum amyloid P component (SAP) in abdominal fat tissue aspirates of patients with amyloidosis
Poster Reinhard Bos, et al: A new classification strategy for systemic amyloidoses using aspirated fat tissue and SELDI proteomics technology
8. EULAR, Paris, 11-14 June 2008
General lecture Bouke P.C. Hazenberg: Novel treatments for amyloidosis
Oral presentation Bregje van Schijndel, et al: Diagnostic performance of a qualitative immunochemical method for detecting ATTR amyloid in aspirated fat tissue
Poster Johan Bijzet et al: Immunochemical analysis of serum amyloid P component (SAP) in abdominal fat tissue aspirates of patients with amyloidosis
Abstract Bouke P.C. Hazenberg, et al: Isolation and purification of Serum amyloid P component from donor blood
Professor P. Westermark (WP2, 5, 6 and 8)
The end of kuru: 50 years of research into a remarkable disease. London, UK, October 2007
The Jan Pontén lecture, Swedish Society of Pathology, Uppsala, Sweden, May 14, 2009
93. Jahrestagung der Deutschen Gesellschaft fur Patologie, Freiburg, Germany June 6, 2009
Industry Forum for prion like diseases, Fontenay-aux-Roses, France, March 22, 2010